SEC Form 4 · accession 0001840199-26-000093
Waldencast plc · WALD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michel Brousset
Officer — Chief Executive Officer · Director
Period of report
Jul 30, 2026
Accepted (ET)
Aug 7, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001840199
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Jul 30, 2026 | D | 264,294 | D | — | — | Class A Ordinary Shares | 264,294 | 0 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.
- F2Represents the Issuer's purchase of 264,294 outstanding RSUs held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.
- F3On October 30, 2024, the reporting person was granted 396,440 RSUs, which would have vested over a three-year period as follows: (i) 132,146 on October 1, 2025; (ii) 132,147 on October 1, 2026; and (iii) 132,147 on October 1, 2027.